New ISPOR Article Compares Net Drug Prices and ICER’s Value-Based Prices

A new article, published in ISPOR’s Value in Health journal, assesses drug prices by comparing net prices to the Institute for Clinical and Economic Review (ICER)’s value-based prices (VBPs). The researchers used 34 ICER reports in their assessment of 102 drugs. The authors note pricing trends in drugs designed for rare diseases and those approved before a published ICER report.

The authors remark, “We reviewed ICER final evidence reports from November 2007 to October 2020. List prices were combined with average discounts obtained from SSR Health to estimate net prices. If a drug had been evaluated more than once for the same indication, only the more recent VBP was included,” adding, “Net prices are often above VBPs estimated by ICER. Although gaining awareness among decision makers, the long-term impact of ICER evaluations on pricing and access to new drugs continues to evolve.” Read more here.

(Source: Bloudek et al., ISPOR, 2021)